Abstract
Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.
Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy
Current Pharmaceutical Design
Title: Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Volume: 16 Issue: 35
Author(s): Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella Giavazzi
Affiliation:
Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy
Abstract: Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.
Export Options
About this article
Cite this article as:
Moschetta Michele, Cesca Marta, Pretto Francesca and Giavazzi Raffaella, Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455021
DOI https://dx.doi.org/10.2174/138161210794455021 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Genetic Determinants of Severe Respiratory Syncytial Virus Infection and Post-Bronchiolitis Wheeze: A Systematic Review
Current Respiratory Medicine Reviews Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Chromium-Picolinate Therapy in Diabetes Care: Molecular and Subcellular Profiling Revealed a Necessity for Individual Outcome Prediction, Personalised Treatment Algorithms & New Guidelines
Infectious Disorders - Drug Targets NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From Molecular Level to Nanotechnology)
Current Pharmaceutical Design Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials